Abstract:
BACKGROUND:Recent molecular characterization studies have identified clinically relevant molecular subtypes to coexist within the same histological entities of glioma. Comparative studies between serum-supplemented and serum-free (SF) culture conditions have demonstrated that SF conditions select for glioma stem-like cells, which superiorly conserve genomic alterations. However, neither the representation of molecular subtypes within SF culture assays nor the molecular distinctions between successful and nonsuccessful attempts have been elucidated. METHODS:A cohort of 261 glioma samples from varying histological grades was documented for SF culture success and clinical outcome. Gene expression and single nucleotide polymorphism arrays were interrogated on a panel of tumors for comparative analysis of SF+ (successful cultures) and SF- (unsuccessful cultures). RESULTS:SF culture outcome was correlated with tumor grade, while no relation was found between SF+ and patient overall survival. Copy number-based hierarchical clustering revealed an absolute separation between SF+ and SF- parental tumors. All SF+ cultures are derived from tumors that are isocitrate dehydrogenase 1 (IDH1) wild type, chromosome 7 amplified, and chromosome 10q deleted. SF- cultures derived from IDH1 mutant tumors demonstrated a fade-out of mutated cells during the first passages. SF+ tumors were enriched for The Cancer Genome Atlas Classical subtype and intrinsic glioma subtype-18. Comparative gene ontology analysis between SF+ and SF- tumors demonstrated enrichment for modules associated with extracellular matrix composition, Hox-gene signaling, and inflammation. CONCLUSION:SF cultures are derived from a subset of parental tumors with a shared molecular background including enrichment for extracellular matrix-associated gene modules. These results provide leads to develop enhanced culture protocols for glioma samples not propagatable under current SF conditions.
journal_name
Neuro Oncoljournal_title
Neuro-oncologyauthors
Balvers RK,Kleijn A,Kloezeman JJ,French PJ,Kremer A,van den Bent MJ,Dirven CM,Leenstra S,Lamfers MLdoi
10.1093/neuonc/not116subject
Has Abstractpub_date
2013-12-01 00:00:00pages
1684-95issue
12eissn
1522-8517issn
1523-5866pii
not116journal_volume
15pub_type
杂志文章相关文献
NEURO-ONCOLOGY文献大全abstract::Patients with the most common and aggressive form of high-grade glioma, glioblastoma multiforme, have poor prognosis and few treatment options. In 2 immunocompetent mouse brain tumor models (CT26-BALB/c and Tu-2449-B6C3F1), we showed that a nonlytic retroviral replicating vector (Toca 511) stably delivers an optimized...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nor199
更新日期:2012-02-01 00:00:00
abstract:BACKGROUND:Promoter methylation of O(6)-methylguanine-DNA methyltransferase (MGMT) is an important predictive biomarker in glioblastoma. The T variant of the MGMT promoter-enhancer single nucleotide polymorphism (SNP; rs16906252) has been associated with the presence of MGMT promoter methylation in other cancers. We ex...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nov064
更新日期:2015-12-01 00:00:00
abstract::The objective of this study was to evaluate whether longitudinal levels of serum YKL-40 correlate with disease status or survival in adults with gliomas. Patients with histologically confirmed gliomas were eligible for this longitudinal study. Serum samples were collected prospectively and concurrently with MRI scans ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nor117
更新日期:2011-11-01 00:00:00
abstract:BACKGROUND:Whole-brain radiotherapy (WBRT) in patients with brain metastases (BM) is associated with neurocognitive decline. Given its crucial role in learning and memory, efforts to mitigate this toxicity have mostly focused on sparing radiation to the hippocampus. We hypothesized that BM are not evenly distributed ac...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noz023
更新日期:2019-05-06 00:00:00
abstract::A phase I trial of an engineered poliovirus for the treatment of recurrent glioblastoma (GBM) has attracted attention due to 8 survivors reaching the 24-month and 5 reaching the 36-month survival landmarks.1 Genetically engineered viruses (oncolytic viruses) have been in trials for GBM for almost two decades.2 These r...
journal_title:Neuro-oncology
pub_type: 杂志文章,评审
doi:10.1093/neuonc/noy170
更新日期:2019-01-01 00:00:00
abstract::Tumor treating fields (TTFields) are low-intensity electric fields alternating at an intermediate frequency (200kHz), which have been demonstrated to block cell division and interfere with organelle assembly. This novel treatment modality has shown promise in a variety of tumor types. It has been evaluated in randomiz...
journal_title:Neuro-oncology
pub_type: 杂志文章,评审
doi:10.1093/neuonc/now182
更新日期:2016-10-01 00:00:00
abstract:BACKGROUND:Diagnostic accuracy in previous studies of O-(2-[18F]-fluoroethyl)-L-tyrosine (18F-FET) PET in patients with suspected recurrent glioma may be influenced by prolonged dynamic PET acquisitions, heterogeneous populations, different non-standard-of-care therapies, and PET scans performed at different time point...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noz166
更新日期:2019-12-17 00:00:00
abstract:Background:Previous reports have shown that overall incidence of malignant brain and other central nervous system (CNS) tumors varied significantly by country. The aim of this study was to estimate histology-specific incidence rates by global region and assess incidence variation by histology and age. Methods:Using da...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nox091
更新日期:2017-10-19 00:00:00
abstract:BACKGROUND:Chemokine signaling may contribute to progression of low-grade gliomas (LGGs) by altering tumor behavior or impacting the tumor microenvironment. In this study, we investigated the role of CX3C chemokine receptor 1 (CX3CR1) signaling in malignant transformation of LGGs. METHODS:Ninety patients with LGGs wer...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noaa075
更新日期:2020-10-14 00:00:00
abstract:BACKGROUND:Diffuse intrinsic pontine glioma (DIPG) is associated with poor survival regardless of therapy. We used volumetric apparent diffusion coefficient (ADC) histogram metrics to determine associations with progression-free survival (PFS) and overall survival (OS) at baseline and after radiation therapy (RT). MET...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nov256
更新日期:2016-05-01 00:00:00
abstract:BACKGROUND:Detection of glioma with MRI contrast agent is limited to cases in which the blood-brain barrier (BBB) is compromised as contrast agents cannot cross the BBB. Thus, an early-stage infiltrating tumor is not detectable. Interleukin-13 receptor alpha 2 (IL-13Rα2), which has been shown to be overexpressed in gli...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nov263
更新日期:2016-05-01 00:00:00
abstract::In this article we report the results of a study of the relationship between response and progression in 375 patients with recurrent glioma enrolled in phase II chemotherapy trials. We reviewed the records of patients from 8 consecutive phase II trials, including 225 patients with recurrent glioblastoma multiforme and...
journal_title:Neuro-oncology
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1093/neuonc/1.4.282
更新日期:1999-10-01 00:00:00
abstract:BACKGROUND:Brain metastases are generally considered to be well demarcated from the surrounding brain parenchyma, although infiltrative growth patterns have been observed. We systemically investigated infiltration patterns and expression of adhesion molecules in a large and well-defined series of autopsy cases of brain...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/not112
更新日期:2013-12-01 00:00:00
abstract:BACKGROUND:More than 90% of patients with diffuse intrinsic pontine glioma (DIPG) will die within 2 years of diagnosis. Patients deteriorate rapidly during the disease course, which severely impairs their quality of life. To date, no specific research on this clinically important subject has been conducted. This study ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nov250
更新日期:2016-04-01 00:00:00
abstract::Treatment for medulloblastoma during childhood impairs neurocognitive function in survivors. While those diagnosed at younger ages are most vulnerable, little is known about the long-term neurocognitive, functional, and physical outcomes in survivors as they approach middle age. In this retrospective cohort study, we ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nor015
更新日期:2011-05-01 00:00:00
abstract::Transforming growth factor-beta (TGF-beta) is a proinvasive and immunosuppressive cytokine that plays a major role in the malignant phenotype of gliomas. One novel strategy of disabling TGF-beta activity in gliomas is to disrupt the signaling cascade at the level of the TGF-beta receptor I (TGF-betaRI) kinase, thus ab...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1215/15228517-2007-010
更新日期:2007-07-01 00:00:00
abstract:BACKGROUND:Breast cancer (BC) is the second most common cause of brain metastases (BM). Optimal management of BM from BC is still debated. In an attempt to provide appropriate treatment and to assist with optimal patient selection, several specific prognostic classifications for BM from BC have been established. We eva...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/not200
更新日期:2014-03-01 00:00:00
abstract:BACKGROUND:Higher-grade meningiomas (HGMs; World Health Organization grades II and III) pose a clinical problem due to high recurrence rates and the absence of effective therapy. Preclinical development of novel therapeutics requires a disease model that recapitulates the genotype and phenotype of patient HGM. Oncolyti...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/now031
更新日期:2016-09-01 00:00:00
abstract:BACKGROUND:Isocitrate dehydrogenase (IDH) mutation status has emerged as an important prognostic marker in gliomas. Currently, reliable IDH mutation determination requires invasive surgical procedures. The purpose of this study was to develop a highly accurate, MRI-based, voxelwise deep-learning IDH classification netw...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noz199
更新日期:2020-03-05 00:00:00
abstract::The effects of combining histone deacetylase (HDAC) inhibitors and proteasome inhibitors were evaluated in both established glioblastoma multiforme (GBM) cell lines and short-term cultures derived from the Mayo Clinic xenograft GBM panel. Coexposure of LBH589 and bortezomib at minimally toxic doses of either drug alon...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1215/15228517-2007-063
更新日期:2008-06-01 00:00:00
abstract:Background:Targeted approaches for treating glioblastoma (GBM) attempted to date have consistently failed, highlighting the imperative for treatment strategies that operate on different mechanistic principles. Bioenergetics deprivation has emerged as an effective therapeutic approach for various tumors. We have previou...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nox243
更新日期:2018-06-18 00:00:00
abstract:BACKGROUND:We report a phase I study to examine the pharmacokinetics, safety, and recommended dosage of weekly intravenous bolus 5-fluorouracil (5-FU) in children and young adults with recurrent ependymoma. METHODS:Patients 22 years of age or less with recurrent ependymoma were treated with bolus dosage 5-FU weekly fo...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nov181
更新日期:2015-12-01 00:00:00
abstract:BACKGROUND:Glioblastoma multiforme (GBM) is characterized by an aggressive clinical course, therapeutic resistance, and striking molecular heterogeneity. GBM-derived brain tumor stem cells (BTSCs) closely model this molecular heterogeneity and likely have a key role in tumor recurrence and therapeutic resistance. Emerg...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nos302
更新日期:2013-02-01 00:00:00
abstract::Treatment of malignant gliomas represents one of the most formidable challenges in oncology. The combination of surgery, radiation, and chemotherapy yields median survivals of less than one year. Here we demonstrate the use of a minimally invasive surgical technique, convection-enhanced delivery (CED), for local admin...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1215/15228517-2006-001
更新日期:2006-07-01 00:00:00
abstract:BACKGROUND:No more than half of patients with neurofibromatosis type 1 (NF1)-associated optic pathway gliomas (OPGs) develop vision loss. Prospectively identifying those who will require therapy remains challenging, because no reliable factors have yet been identified that predict future vision loss. To determine wheth...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/not068
更新日期:2013-08-01 00:00:00
abstract::Effective treatment of glioblastoma (GBM) remains a formidable challenge. Survival rates remain poor despite decades of clinical trials of conventional and novel, biologically targeted therapeutics. There is considerable evidence that most of these therapeutics do not reach their targets in the brain when administered...
journal_title:Neuro-oncology
pub_type: 杂志文章,评审
doi:10.1093/neuonc/nou354
更新日期:2015-03-01 00:00:00
abstract::High-grade gliomas release excitotoxic concentrations of glutamate, which has been shown to enhance tumor proliferation and migration. alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) glutamate receptors are abundantly expressed at the invading edge of glioblastoma specimens, suggesting they may play an...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1215/15228517-2008-094
更新日期:2009-06-01 00:00:00
abstract::Current treatments for brain cancer have, for the most part, equivocal survival benefit. However, clinical trials of new anticancer agents do not adequately assess potential clinical benefits for patient function other than survival and time to tumor progression. We evaluated 56 patients with recurrent brain tumors wh...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/5.2.89
更新日期:2003-04-01 00:00:00
abstract:BACKGROUND:Expression of programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) across glioma grades is undocumented, and their interactions with commonly expressed genetic and epigenetic alterations are undefined but nonetheless highly relevant to combinatorial treatments. METHODS:Patients with CNS ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/now132
更新日期:2016-10-01 00:00:00
abstract::We have previously demonstrated that chordomas express activated platelet-derived growth factor receptor (PDGFRB) and that treatment with imatinib, which is capable of switching off the activation of various receptor tyrosine kinases (RTKs) including PDGFRB, benefits a number of patients. The aim of this study was to ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noq003
更新日期:2010-08-01 00:00:00